CSF3 and Cirrhosis: A recent multicenter phase-II open-label controlled trial of HSCs was completed in which repeated autologous infusions of G-CSF-mobilized CD133 + cells were administered to patients with advanced cirrhosis (versus conservative management or treatment with G-CSF alone) (Newsome et al., 2018).